In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4^th Cell Therapy Potency Assay Summit, uniting AD, QC and regulatory experts, this summit works to design potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies.

Join leading organizations like Arsenal Biosciences, BlueRock Therapeutics, the NIST and Vertex Pharmaceuticals, as they share development strategies and the latest technologies needed to streamline your assay development workflows. You won’t want to miss out!

To know more visit: https://ter.li/inqax5